Epoch Times - A New Experimental Active Immunotherapy for Treating Alzheimer’s | Lou Reese
Aired: 2026-01-23
Duration: 02:30


=== Gently Activating the Immune System (02:30) ===

[00:00:00]  What if we can gently turn on the immune system to only generate these antibodies?
[00:00:04]  No off-site reactions.
[00:00:05]  The typical vaccine, as an example, generates over 95% towards the toxic carrier.
[00:00:11]  That could be KLH, that could be any of the carriers, and less than 5% to the actual target.
[00:00:17]  That's why immune systems get...
[00:00:18]  And just to summarize, basically you're saying when you do a typical vaccine, most of the antibodies created are not...
[00:00:25]  Yeah, virtually all are actively against the wrong thing.
[00:00:28]  So in effect, think of it as riling up the immune system to get a minor response.
[00:00:33]  What we do is actually, it's much more like CLTM6.
[00:00:36]  We come in completely silently and the outcome is, so the immune system is completely silent, and then we take out the bad guys.
[00:00:44]  So we pick up Maduro, there's no casualties, and we're out, right?
[00:00:47]  And so that's what we designed.
[00:00:49]  It was made for that.
[00:00:51]  And that's exactly what we see in the clinic and in patients.
[00:00:54]  And so in the future, and what I believe and what is true is that we can go where antibodies and monoclonals and biologics can't go, which is we can do multiple targets at the same time.
[00:01:05]  We can go after multiple targets of the same protein or the same hormone that's causing autoimmune diseases.
[00:01:11]  We can go after the thing that is causing Alzheimer's in this case, which is the toxic oligomeric and febrile forms of A-beta.
[00:01:17]  That's the beginning of the decline.
[00:01:19]  That's what people colloquially know as amyloid plaque, right?
[00:01:23]  So actually, no.
[00:01:25]  Plaque is a surrogate marker that can be measured easily by PET scan.
[00:01:29]  It turns out that there are a huge number of Alzheimer's patients that do not have plaques.
[00:01:33]  The reason that the side effects for going after the plaque are so horrendous in the existing drugs is that you have 17 to 34 percent rates of REE.
[00:01:44]  That's a fancy formula.
[00:01:46]  Brain swelling.
[00:01:47]  Brain swelling.
[00:01:48]  And all of the current approved therapies are monoclonal antibodies.
[00:01:52]  The dilemma with those is that they're expensive, difficult to administer, and have these side effects.
[00:01:57]  And so they're just not possible to use those in any way for prevention.
[00:02:02]  So we basically generate only those specific antibodies, and they actually change, it's called antibody maturation, to match your personal version of those toxic oligomers and fibrils.
[00:02:15]  So this is a personalized medicine approach.
[00:02:17]  So it triggers your body to make those antibodies in quantity, and then it breaks up those fibrils and actually covers them with dendrites in the brain.
[00:02:27]  And then that naturally alerts the immune system to clear them.